Hyperthermia in cancer treatment (I).
In recent years there have been numerous randomized and nonrandomized studies conducted to assess the efficacy of hyperthermia combined with either radiation therapy or chemotherapy especially in the treatment of superficially seated malignant tumors. The major impact of hyperthermia is currently on loco-regional control of tumor. Heat may be directly cytotoxic to tumor cells or inhibit repair of both sublethal and potentially lethal damage after radiation. These effects are augmented by the physiological conditions in tumor which lead to states of acidosis and hypoxia. Blood flow is often impaired in tumor relative to normal tissue, and hyperthermia may lead to a further decrease in blood flow and augment heat-sensitivity. Three major areas of clinical investigation have borne the greatest fruit for hyperthermia as adjunctive therapy to radiation therapy. These include recurrent and primary breast lesions, melanoma, and head and neck neoplasms. Thermal enhancement ratio was increased in all cases and is estimated to be 1.4 for neck nodes, 1.5 for breast and 2 for malignant melanoma. In general, the most important prognostic factors for complete response are radiation dose, tumor size and minimal thermal parameters (minimal thermal dose (t43min), mean minimal temperature (Tmin) or T90, i.e., temperature exceeded by 90% of thermal sensors). The number of heat fractions administered per week appears to have no bearing on the overall response, which may be indicative of the effects of thermotolerance. The total number of heat fractions delivered also appears irrelevant provided adequate heat is delivered in one or two sessions. The major prognostic factors for the duration of local control are tumor histology, concurrent radiation therapy, dose, tumor depth and Tmin.
Engin
K
K
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107-5097.
D002986:Clinical Trials as Topic; D006801:Humans; D006979:Hyperthermia, Induced; D009369:Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic